{
  "meta": {
    "title": "Basic_Pharmacology",
    "url": "https://brainandscalpel.vercel.app/basic-pharmacology-a35baea9.html",
    "scrapedAt": "2025-11-30T08:50:51.988Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">15mg</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">30mg</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">40mg</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">60mg</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 8 year old boy is brought to the emergency room by his mother. One hour ago, he ingested an unknown quantity of one of her prescription medications. Serum testing shows the boy's drug level is 5 mg/dL. The drug is known to have a half- life of 1 hour, a volume of distribution of 150 ml, a bioavailability of 50%, and follow first-order elimination kinetics. Which of the following doses of the drug did the boy ingest?</span></p>",
      "unique_key": "DT1292965",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292965,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><em>Initially considering 100% Bioavailability</em></strong></p>\r\n<ul>\r\n<li>Volume of distribution is 150 ml that is 0.15 L or 150 * 10/1000 ml</li>\r\n<li>Total dose = (drug)* Vd</li>\r\n</ul>\r\n<p>= 10 mg/dl* 150ml *10 dl/1000ml</p>\r\n<p>=15mg</p>\r\n<p><strong><em>Considering 50% Bioavailability</em></strong> dose should be <u>doubled to 30 mg</u>.</p>\r\n<ul>\r\n<li>The drug has a <em>1 hour half-life</em> and was ingested one hour ago so initial drug level was twice the current level.</li>\r\n<li>Thus, the <strong>initial serum concentration</strong> shortly after ingestion was <strong>10 mg/dL (5 x 2)</strong></li>\r\n<li>Serum level multiplied by volume of distribution is equal to dose at 100% bioavailability.</li>\r\n<li>If we multiply 10 mg/dL x 150 ml (volume of distribution) x 10dl/1000 ml we get 15 mg for the initial amount in the body,</li>\r\n</ul>\r\n<p>With a <strong><em>50% bioavailability, the ingested amount was 15*2 or 30 mg.</em></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024122181d00c14-7142-4c97-85e1-c99b478fa588.jpg\">\r\n<p><strong><u>Key Takeaway</u></strong></p>\r\n<p><strong>Bioavailability</strong></p>\r\n<ul>\r\n<li>It is the <strong><em>fraction of administered drug that reaches the systemic circulation in the unchanged form</em></strong>.</li>\r\n<li>When we administer a drug orally, first it is absorbed into the portal circulation and reaches the liver.</li>\r\n<li>Here, some of the drug may be metabolized (<em>first pass metabolism or pre-systemic metabolism</em>) and rest of the drug reaches the systemic circulation.</li>\r\n<li>Thus, <strong><em>absorption and first pass metabolism are two important determinants of bioavailability</em></strong>.</li>\r\n</ul>",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">37.5 mg</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">100 mg</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">375 mg</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">750 mg</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45 year old man is started on an intravenous drug for treatment of seizures. His weight is 75 kg. The drug has a volume of distribution of 0.5 L/kg. If the desired serum concentration is 20 mg/L, what is the appropriate loading dose?</span></p>",
      "unique_key": "DT1292966",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292966,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong><em>Loading Dose = (Drug) * Vd / F</em></strong></li>\r\n<li>*Vd is volume of distribution = 0.5 (L/kg)*75 kg = 37.5 L</li>\r\n<li>F = Bioavailability (IV route has a bioavailability of 100%)</li>\r\n<li>The loading dose is equal to the desired drug concentration times the volume of distribution divided by bioavailability.</li>\r\n<li>Since the drug is administered intravenously, <strong><em>bioavailability is 100%.</em></strong></li>\r\n<li><strong><em>Thus, the loading dose is 20 (mg/L)*0.5 (L/kg)*75 kg </em></strong></li>\r\n</ul>\r\n<p><strong><em>= 20 (mg/L)* 37.5 L</em></strong></p>\r\n<p><strong><em>= 750 mg.</em></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241221230d5550-1079-43a5-ad62-109ff8613046.jpg\">\r\n<p><strong><u>Key Takeaway</u></strong></p>\r\n<ul>\r\n<li><strong>Volume of distribution </strong>(<em>Vd</em>).</li>\r\n<li>It is the volume that would be required to contain the administered dose if that dose was evenly distributed at the concentration measured in plasma.</li>\r\n<li>It depends on several factors like lipid solubility and plasma protein binding</li>\r\n<li><strong>Loading dose: </strong>It is mainly used for drugs having long t&frac12; and large volume of distribution. It is given to load (saturate) the tissue stores. So it is mainly dependent on V<em>d</em>.</li>\r\n<li><strong><em>Loading dose = Vd &times; Target plasma concentration</em></strong></li>\r\n</ul>",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased bioavailability</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased volume of distribution</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Accumulation of morphine metabolites</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibition of liver P450 enzymes</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An 82 year old man is admitted to the hospital after a road traffic accident. Intravenous morphine is administered at regular intervals for control of bone pain. Two days later his creatinine increases from 1.0 to 2.3 mg/dL with impending renal failure. He is noted to be lethargic with shallow respirations. Naloxone is administered and he becomes more alert with increased respirations. Which of the following may explain his response to morphine?</span></p>",
      "unique_key": "DT1292967",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292967,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Morphine is an <strong><em>opioid used for pain control</em></strong>.</li>\r\n<li>It is metabolized in the liver via <strong><em>glucuronidation (phase II metabolism) to morphine-6-glucuronide (M6G) and morphine-3- glucuronide (M3G</em></strong>), which can be <strong><em>excreted in the urine.</em></strong></li>\r\n<li>As he has <strong>deteriorating renal function</strong> as reflected by a rise in serum creatinine, this has <strong><em>led to an accumulation of morphine metabolites</em></strong></li>\r\n</ul>\r\n<p><strong>Option A</strong> : <em>Bioavailability is the fraction of a drug dose that reaches the systemic circulation. </em></p>\r\n<p><strong>Option B: </strong>Volume of distribution is the theoretical volume a drug occupies in the body.</p>\r\n<p><strong>Option D : </strong>Cytochrome P450 enzymes are not much involved in metabolism of morphine.</p>\r\n<p><strong><u>Key Takeaway</u></strong></p>\r\n<ul>\r\n<li><strong>Volume of distribution </strong>(<em>Vd</em>).</li>\r\n<li>It is the volume that would be required to contain the administered dose if that dose was evenly distributed at the concentration measured in plasma.</li>\r\n<li>It depends on several factors like lipid solubility and plasma protein binding</li>\r\n</ul>",
      "correct_choice_id": 23,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">First order</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Zero order</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Flow dependent</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Capacity dependent</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Researchers are studying alcohol metabolism among healthy volunteers. They are asked to consume several glasses of alcohol over a 1-hour period. Blood samples are obtained at regular intervals to measure serum alcohol concentration. Based on body weight, total body alcohol content is determined and elimination rate of alcohol is calculated. Data are shown in the table below. Which of the following best describes the elimination of ethanol?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024122106d872d9-cf8e-4a0d-9155-2ad47de155cf.jpg\"></span></p>",
      "unique_key": "DT1292968",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292968,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>The elimination <em>rate of </em><em>ethanol increases as the serum concentration rises until about 80 mg/dl,</em> and <strong><u>then remains constant.</u></strong></li>\r\n<li>This is consistent with <strong><em>capacity dependent elimination.</em></strong> Drugs with capacity dependent elimination have <strong><em>excretion mechanisms that become saturated at high drug concentrations. </em></strong></li>\r\n<li>In the case of ethanol, the <strong><u>enzyme alcohol dehydrogenase oxidizes ethanol but becomes saturated at high serum concentrations</u></strong></li>\r\n<li>At these concentrations, metabolism is <strong><em>following Michaelis-Menten kinetics and varying with serum level.</em></strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412217fc433dc-a302-4be4-b51d-d135e00c9c91.jpg\">\r\n<p><strong>Option A : </strong><strong><em>First order kinetics</em></strong> The rate <em>of elimination is directly proportional to the drug concentration</em>, <strong><em>CL </em>remains constant</strong>; or a <u>constant <em>fraction </em>of the drug present in the body is eliminated in unit time. </u></p>\r\n<p><strong>Option B</strong> : <strong><em>Zero order kinetics</em></strong> The <strong><em>rate of elimination remains constant irrespective of drug concentration</em></strong>, <em>CL </em>decreases with increase in concentration; or a <strong><em>constant amount of the drug is eliminated in unit</em></strong> <strong><em>time</em></strong></p>\r\n<p><strong>Option C</strong> <em>: <strong>Blood flow dependent elimination</strong> </em>For few drugs the <strong><em>eliminating capacity of an organ of elimination (kidney, liver) far exceeds the amount of drug normally presented to it by blood circulation</em></strong>. The elimination of such a drug becomes blood flow dependent</p>\r\n<p><strong><u>Key Takeaway</u></strong></p>\r\n<ul>\r\n<li><strong><em>Zero order kinetics </em></strong></li>\r\n<li>The <strong>rate of elimination remains constant irrespective of drug concentration</strong>, <em>CL </em>decreases with increase in concentration; or a constant <em>amount </em>of the drug is eliminated in unit time, e.g. ethyl alcohol.</li>\r\n<li>This is also called <strong><em>capacity limited elimination </em>or <em>Michaelis-Menten elimination.</em></strong></li>\r\n<li>The <strong>elimination of some drugs approaches saturation over the therapeutic range, kinetics changes from first order to zero order at higher doses</strong>.</li>\r\n<li>As a result <u>plasma concentration increases disproportionately with increase in dose</u></li>\r\n</ul>",
      "correct_choice_id": 34,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">15.0 mg/dL</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">14.2 mg/dL</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">12.8 mg/dL</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">8.0 mg/dL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45 year old hospitalized patient is administered 100 mg of a particular drug. Shortly after administration, serum level of the drug is 20 mg/dL. One hour after that, serum drug concentration is 16 mg/dL. If the drug follows first-order elimination kinetics, what will the serum concentration be in another hour?</span></p>",
      "unique_key": "DT1292969",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292969,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><em><u>First order kinetics</u></em></strong></p>\r\n<ul>\r\n<li>The rate <em>of elimination is directly proportional to the drug concentration</em>, <strong><em>CL </em>remains constant</strong>; or a <u>constant <em>fraction </em>of the drug present in the body is eliminated in unit time.</u></li>\r\n<li>Drugs that follow first-order elimination kinetics have <strong><em>serum concentrations that fall by a constant percentage per unit time. </em></strong></li>\r\n<li>These drugs have a constant half-life, meaning the time for a <em>50% reduction in concentration is always the same. </em></li>\r\n<li>During the first hour, <strong><em>drug concentration fell from 20 to 16 mg/dL. A 20% decrease.</em></strong></li>\r\n<li>Therefore, in the next hour <strong><em>concentration will again fall by 20% to a concentration of 12.8 mg/dL</em></strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412213c947c01-ab06-4ed8-ac2f-7eaf016abcd0.jpg\">\r\n<p><strong><u>Key Takeaway</u></strong></p>\r\n<ul>\r\n<li><strong><em>First order kinetics </em></strong></li>\r\n<li>The <strong><em>rate of elimination is directly proportional to the drug concentration, CL remains constant</em></strong>; or a constant <em>fraction </em>of the drug present in the body is eliminated in unit time.</li>\r\n<li>This applies to majority of drugs which do not saturate the elimination processes (transporters, enzymes, blood flow, etc.) over the therapeutic concentration range.</li>\r\n</ul>",
      "correct_choice_id": 43,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">17 L</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">60 L</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">10 L</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">80 L</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65 year old man with a history of myocardial infarction is admitted to the hospital for treatment of atrial fibrillation with rapid ventricular response. He  weighs around 80 kg. He is given an intravenous bolus of 150 mg of amiodarone. After 20 minutes, the amiodarone plasma concentration is 2.5 &mu;g/mL. Amiodarone distributes in the body within minutes, and its elimination half-life after intravenous administration is 30 days. Which of the following values is closest to the volume of distribution of the administered drug?</span></p>",
      "unique_key": "DT1292970",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292970,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong><em>The volume of distribution (Vd) is calculated by dividing the total amount of the drug in the body by its plasma concentration.</em></strong></li>\r\n<li><strong><em>Vd = Dose administered (I.V.) / Plasma concentration</em></strong></li>\r\n<li>Since the <em>half-life of amiodarone is extremely long</em>, only a negligible amount of the drug would be eliminated from the body after 20 minutes, meaning that <em>the total drug amount in the body after this time would approximately be equivalent to the amount of the drug administered.</em></li>\r\n</ul>\r\n<p>The total drug amount is</p>\r\n<p><strong><em>150 mg (150,000 &mu;g)</em></strong> and plasma concentration is <strong>2.5 &mu;g/mL.</strong></p>\r\n<p><strong><em>Vd = Dose administered (I.V.) / Plasma concentration</em></strong></p>\r\n<p><strong><em>Vd = 150,000/2.5</em></strong></p>\r\n<p><strong><em>= 60,000 mL (60 L).</em></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024122139147573-7cdb-47f9-972e-096f89b2456a.jpg\">\r\n<p><strong><u>Key Takeaway</u></strong></p>\r\n<ul>\r\n<li><strong>Volume of distribution </strong>(<em>Vd</em>).</li>\r\n<li>It is the volume that would be required to contain the administered dose if that dose was evenly distributed at the concentration measured in plasma.</li>\r\n<li>It depends on several factors like lipid solubility and plasma protein binding</li>\r\n</ul>",
      "correct_choice_id": 52,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">High Bioavailability</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Extensive first-pass metabolism</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Low volume of distribution</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Delayed clearance</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56 year old man with coronary artery disease agrees to participate in a pharmacological study. He was given an oral & Intravenous formulation. An investigator measures the plasma concentration of the drug over time after intravenous and then after oral administration. There is no statistically significant difference in the dose-corrected area under the curve (AUC) for the two routes of administration. Which of the following is the most likely explanation for this finding?</span></p>",
      "unique_key": "DT1292971",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292971,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong><em>Bioavailability describes the rate and concentration at which the drug appears in circulation and is expressed as a percentage of the dose that was initially administered.</em></strong></li>\r\n<li>In this case, <strong><em>oral administration of the drug shows no statistically significant difference in the dose-corrected AUC from intravenous administration, indicating that this <u>drug has near 100% bioavailability.</u></em></strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024122122921b24-0615-4aee-a377-6e3a70dff93a.jpg\">\r\n<p><strong>Option B:</strong><br /> If the drug has extensive first-pass metabolism, it <strong><em>would show a significantly reduced AUC relative to the AUC for an intravenously administered drug</em></strong>; the AUC for oral administration is not reduced.</p>\r\n<p><strong>Option C</strong>:<br /> Drugs with a <strong><em>low volume of distribution are often not lipophilic and therefore tend to be restricted to the intravascular compartment</em></strong>.</p>\r\n<p><strong>Option D</strong>:<br /> Clearance is inversely proportional to the AUC; the <strong><em>more delayed the clearance of a drug is, the longer the drug stays in the body</em></strong>, and the higher the AUC is.</p>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong>Bioavailability</strong></li>\r\n<li>It is the <strong><em>fraction of administered drug that reaches the systemic circulation in the unchanged form</em></strong>.</li>\r\n<li>When we administer a drug orally, first it is absorbed into the portal circulation and reaches the liver.</li>\r\n<li>Here, some of the drug may be metabolized (<em>first pass metabolism or pre-systemic metabolism</em>) and rest of the drug reaches the systemic circulation.</li>\r\n<li>Thus, <strong><em>absorption and first pass metabolism are two important determinants of bioavailability</em></strong>.</li>\r\n</ul>",
      "correct_choice_id": 61,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">CYP2E1</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">CYP2D6</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">CYP3A4</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">CYP2C19</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 58 year old man comes to the physician because of severe muscle aches and fatigue for 3 days. Last week he was diagnosed with atypical pneumonia and treated with clarithromycin. He has hyperlipidemia for which he takes lovastatin. Physical examination shows generalized tenderness of the proximal muscles in the upper and lower extremities. Serum studies show an elevated creatinine kinase concentration. This patient's current symptoms are most likely caused by inhibition of which of the following hepatic enzymes?</span></p>",
      "unique_key": "DT1292973",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292973,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>The <strong><em>risk of statin-induced toxic myopathy increases with the addition of cytochrome CYP3A4 inhibitors, which include the macrolides, clarithromycin and erythromycin (not azithromycin).</em></strong></li>\r\n<li><strong><em>Lipophilic statins such as simvastatin, atorvastatin, and lovastatin have a higher propensity to cause myopathy than do hydrophilic agents (pravastatin, rosuvastatin), which are not significantly metabolized by CYP3A4.</em></strong></li>\r\n</ul>\r\n<p><strong><u>Mnemonic</u></strong></p>\r\n<ul>\r\n<li><strong><u>Enzyme inhibitors </u></strong><strong>[ </strong><strong><em>Virat Kohli Can&rsquo;t Call Every Indians</em></strong><strong>]</strong></li>\r\n<li><strong><u>V</u></strong>alproate</li>\r\n<li><strong><u>K</u></strong>etoconazole</li>\r\n<li><strong><u>C</u></strong>imetidine</li>\r\n<li><strong><u>C</u></strong>iprofloxacin/<strong><u>C</u></strong>larithromycin</li>\r\n<li><strong><u>E</u></strong>rythromycin</li>\r\n<li><strong><u>I</u></strong>NH</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241221b3f960a0-7dd0-4147-b507-65088f61b197.jpg\">\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong>Enzyme inhibitors </strong>will <strong><em>decrease the metabolism of drugs metabolized by microsomal enzymes, thus predisposes to the toxicity by such agents</em></strong>.</li>\r\n<li>Inhibitors include <strong>ketoconazole, cimetidine, erythromycin and metronidazole</strong>.</li>\r\n</ul>",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">270 mg</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">480 mg</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">135 mg</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">240 mg</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56 year old patient is being treated with oral amoxicillin for community-acquired pneumonia. The plasma clearance of the drug is calculated as 15 L/h. Oral bioavailability of the drug is 75%. The target plasma concentration is 2 mg/L. If the drug is administered twice per day, which of the following dosages should be administered at each dosing interval to maintain a steady state?</span></p>",
      "unique_key": "DT1292974",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292974,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>A maintenance dose of <strong><em>480 mg should be administered at 12 hour intervals to achieve the desired target concentration of 2 mg/L.</em></strong></p>\r\n<p>The corresponding formula needed for calculation requires the following values: <br /> <br /> <strong>Cp = target plasma concentration at steady state (mg/L)<br /> Cl = clearance (L/h)<br /> &tau; = dosing interval (hours)<br /> F = bioavailability <br /> <br /> Maintenance dose = (Cp * Cl * &tau;) / F </strong></p>\r\n<p><strong>&rarr; (2*15*12)/0.75 </strong></p>\r\n<p><strong>= 360/0.75 </strong></p>\r\n<p><strong>= 480 </strong></p>\r\n<p><strong><u>Key Takeaway</u></strong></p>\r\n<ul>\r\n<li><strong>Steady State</strong></li>\r\n<li>If fixed dose of a drug is administered after regular intervals, its plasma Concentration starts increasing.</li>\r\n<li>However, as plasma concentration rises, rate of elimination also starts increasing. <strong><em>When rate of administration becomes equal to rate of elimination, plasma concentration stabilizes. This is called steady state</em></strong>.</li>\r\n<li>Time to reach steady state depends on t&frac12;. It takes approximately 5 half lives.</li>\r\n<li>Steady state plasma concentration achieved depends on dose rate.</li>\r\n<li>Variation between peak and trough concentration at steady state depends on dosing interval.</li>\r\n</ul>",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Non-competitive antagonist</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Competitive antagonist</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Inverse agonist</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Full agonist</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An investigator is studying the interaction between a new drug B and an existing drug A. The results are recorded and plotted on the graph shown. Which of the following properties of drug B best explain the observed effect on the dose-response curve of drug A?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412218988b217-c33b-4db0-9be0-1f09d3072895.jpg\"></span></p>",
      "unique_key": "DT1292975",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292975,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong><em>Competitive antagonists block the binding site of the drugs</em></strong> that they antagonize and would cause <strong><em>the original dose-response curve to shift to the right reflecting a decrease in potency.</em></strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412218ed56d43-2c02-4451-a0a7-d3ad8e9257c9.jpg\">\r\n<p><strong>Option A</strong>: <strong><em>Non-competitive antagonists can either cause a conformational change</em></strong> or bind to the active site of the <strong><em>receptor allosterically</em></strong>.</p>\r\n<p>This <strong><em>decreases the binding of the agonist, which cannot be overcome by increasing doses of the agonist.</em></strong></p>\r\n<p><strong>Option C</strong>: <strong><em>An inverse agonist would bind to the same receptor but has a different binding site than an agonist</em></strong> and typically elicits the <em>opposite of the agonistic effect</em></p>\r\n<p><strong>Option D</strong>: A <strong><em>full agonist would have the same potency and efficacy as the original drug. Therefore, the dose-response curve would remain unchanged.</em></strong></p>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><em><u>DRC can be utilized to know whether a drug is competitive or noncompetitive inhibitor</u></em>.</li>\r\n<li><strong>In case of competitive inhibitor, curve will shift to right</strong>, i.e. now the same agonist will have less potency in the presence of antagonist. It does not affect the efficacy.</li>\r\n<li>In case of <strong>noncompetitive inhibitor</strong>, there will be <strong>flattening of DRC</strong>, i.e. efficacy decreases. It usually does not affect potency.</li>\r\n<li>If the antagonist is <strong>irreversible competitive</strong>, then there will be <em>decrease in potency as well as efficacy.</em></li>\r\n</ul>",
      "correct_choice_id": 92,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug C is more effective than drugs A or B</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug C is more potent than drugs A or B</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Drugs A and B have the same potency</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug B is less potent than drug A</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Three hypertension drugs are evaluated in a study. Patients with stage I hypertension are recruited and assigned to varying dosages of drug A, B, or C. Data are shown below for the percentage of patients achieving a decrease of 10 mmHg in systolic blood pressure. Which of the following statement is true?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024122126893284-4054-486f-b58f-cd6c510d6c0b.jpg\"></span></p>",
      "unique_key": "DT1292977",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292977,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong><em>Drug A achieves its effects at the low end of the x-axis. This indicates a more potent drug that requires a lower dosage to achieve any particular effect compared with A and C.</em></strong></li>\r\n<li><strong><em>Drug B can achieve the same maximum effectiveness as drug A, but only at a higher dosage. </em></strong></li>\r\n<li>Thus, <strong><em><u>drug B is less potent than drug A.</u></em></strong></li>\r\n</ul>\r\n<p><strong><u>Key Takeaway</u></strong></p>\r\n<ul>\r\n<li><strong>Potency</strong></li>\r\n<li><strong><em>It is the measure of the amount of a drug needed to produce the response.</em></strong></li>\r\n<li><em>Drugs producing the same response at lower dose are more potent </em>whereas those requiring large dose are less potent. <em>In DRC, more a drug is on left side </em>of the graph, <em>higher is its potency </em>and vice a versa</li>\r\n</ul>",
      "correct_choice_id": 104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">The potency will decrease</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">The potency will increase</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">The efficacy will decrease</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">The efficacy will increase</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An experimental drug is administered to the patient in the form of an inactive prodrug. The prodrug itself increases the expression of a cytochrome P-450 that converts the prodrug to its active form. With chronic, long-term administration of the prodrug, which of the following will be observed?</span></p>",
      "unique_key": "DT1292978",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292978,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>The <strong><em>induction of the cytochrome P-450 following chronic administration will increase the conversion of the inactive prodrug to the active form</em></strong>.</li>\r\n<li>This will <strong><em>shift the dose response curve of the prodrug to the left</em></strong> (i.e., <strong><em>increase its potency) without changing its efficacy.</em></strong></li>\r\n</ul>\r\n<p><u>Biotransformation of drugs may lead to the following.</u></p>\r\n<ul>\r\n<li><strong><em>Inactivation </em></strong>\r\n<ul>\r\n<li><strong><em>Most drugs and their active metabolites are rendered inactive or less active,</em></strong></li>\r\n<li>Thus, <em>biotransformation provides an alternative method of terminating&nbsp;</em><em>drug action to excretion.</em></li>\r\n</ul>\r\n</li>\r\n<li><strong><em>Active metabolite from an active drug</em></strong>\r\n<ul>\r\n<li>Many drugs have been found to be <strong><em>partially converted to one or more active metabolite; </em></strong></li>\r\n<li>The effects observed are the sum total of that due to the parent drug and its active metabolite(s)</li>\r\n</ul>\r\n</li>\r\n<li><strong><em>Activation of inactive drug </em></strong>\r\n<ul>\r\n<li>Few drugs are <strong><em>inactive as such and need conversion in the body to one or more active metabolites</em></strong>. Such a drug is called a <strong><em>prodrug</em></strong></li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p>The <strong><u>prodrug may offer advantages over the active form</u></strong></p>\r\n<ul>\r\n<li><strong><em>Being more stable, </em></strong></li>\r\n<li><strong><em>Better bioavailability </em></strong></li>\r\n<li><strong><em>Desirable pharmacokinetic properties</em></strong></li>\r\n<li><strong><em>Less side effects and toxicity</em></strong></li>\r\n</ul>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li>Few drugs are <strong><em>inactive as such and need conversion in the body to one or more active metabolites</em></strong>.</li>\r\n<li>After chronically being converted to active metabolite by enzymes, it will ultimately increase the potency of the given drug.</li>\r\n</ul>",
      "correct_choice_id": 112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Competitive antagonist</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Non-competitive antagonist</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Full agonist</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Partial agonist</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A principal investigator is evaluating a known drug interacting with beta receptors. Healthy volunteers are recruited and assigned to varying dosages of epinephrine or the study drug. Data are shown below for the percentage of patients achieving an increase of 10/min in heart rate. Which of the following best describes the drug's effect on beta receptors?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024122108ef9213-e1e1-4847-93bc-b0ab27c0146d.jpg\"></span></p>",
      "unique_key": "DT1292980",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292980,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>The graph shows a <strong><em>dose-response curve for epinephrine and the study drug</em></strong></li>\r\n<li>As the <strong><em>concentration of substrate rises, there is a rise in pulse rate among patients</em></strong>. This indicates both <strong><em>substrates are agonists to beta receptors</em></strong>.</li>\r\n<li>The drug achieves a <em>lesser effect compared to epinephrine, a finding consistent with a partial agonist.</em></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241221395d17b9-6fd0-400f-9fd4-d566f2d57cd9.jpg\">\r\n<p><strong>Option A</strong>: <strong><em>Competitive antagonist</em></strong></p>\r\n<p>The antagonist is <strong><em>chemically similar to the agonist, competes with it</em></strong> and binds to the <strong>same site</strong> of the agonist molecules.</p>\r\n<p>Because the <strong><em>antagonist has affinity but no intrinsic activity</em></strong>, no response is produced and the <strong><em>log DRC of the agonist is shifted to the right</em></strong>.</p>\r\n<p><strong>Option B</strong></p>\r\n<p><strong><em>Noncompetitive antagonism</em></strong></p>\r\n<p>The antagonist is <strong><em>chemically unrelated to the agonist</em></strong>, binds to a <strong><em>different allosteric site altering the receptor</em></strong> in such a way that it is unable to combine with the agonist or is unable to transduce the response.</p>\r\n<p><strong><em>Increasing concentrations of the antagonist progressively flatten the agonist DRC</em></strong></p>\r\n<p><strong>Option C</strong>: A <strong><em>full agonist would demonstrate the same effect as epinephrine</em></strong>.</p>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong><em>Partial agonist</em></strong>\r\n<ul>\r\n<li>An <strong><em>agent which activates a receptor to produce submaximal effect but </em></strong><strong><em>antagonizes the action of a full agonist</em></strong><strong><em>.</em></strong></li>\r\n</ul>\r\n</li>\r\n</ul>",
      "correct_choice_id": 124,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Has low potency but high efficacy</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Has affinity but lacks efficacy</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Blocks the effect of the antagonist</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Cannot produce the full effect, even at high doses</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements best describes the partial agonist?</span></p>",
      "unique_key": "DT1292981",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292981,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong><em>An agonist</em></strong> acts at its receptor to <em>activate the signal transduction pathway and produce an effect.</em></li>\r\n<li><strong><em>An antagonist</em></strong> binds to its receptor, producing no effect at the receptor, but rather blocks the receptor so that agonists cannot bind and produce an effect.</li>\r\n<li><strong><em>A partial agonist binds to the receptor and activates the signal transduction pathway, but not to the maximal degree</em></strong>.</li>\r\n<li>Because the degree to which a ligand activates its receptor is called <em>efficacy, </em>it is clear that <strong><em>partial agonists do not have full efficacy</em></strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412219ce5bd1e-ac83-4f76-a916-e6703be4b101.jpg\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024122178fb13cd-a7b1-4374-b098-ff48fcdef26e.jpg\">\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong><em>Partial agonist </em></strong></li>\r\n<li>An <strong><em>agent which activates a receptor to produce submaximal effect but antagonizes the action of a full agonist</em></strong><strong><em>.</em></strong></li>\r\n</ul>",
      "correct_choice_id": 134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">0 to 5</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">5 to 15</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">5 to 20</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">15 to 30</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An investigator has enrolled few patients with schizophrenia who are being administered haloperidol at a range of dosages in a tertiary health care hospital. Serum levels of haloperidol are measured for each patient. Patients with reduction in positive symptoms are considered responders to therapy and patients with any extrapyramidal side effect are considered to have toxicity of therapy (Shown below in a graph). Which of the following ranges represents the therapeutic window of haloperidol (ng/ml)?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412215ea7d5f5-df7c-48a8-b443-dee32bf14a7b.jpg\"></span></p>",
      "unique_key": "DT1292983",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292983,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>The <strong><em>therapeutic window is the range of dosages that produces a therapeutic response without causing adverse effects.</em></strong></li>\r\n<li>From the graph, the <strong><em>first responders to therapy occur at a serum level of 5 ng/ml. </em></strong></li>\r\n<li>The first patients with <strong><em>evidence of toxicity occur at about 15 ng/ml</em></strong></li>\r\n<li>Thus, the <strong><em>therapeutic window is 5 to 15 ng/ml.</em></strong></li>\r\n</ul>\r\n<p><strong>'Therapeutic window' is bounded by the dose which produces <u>minimal therapeutic effect and the dose which produces maximal acceptable adverse effect</u></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241221166194ce-fc81-4d03-a57a-95a1e8baabe0.jpg\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241221e96d0a11-e907-419e-9f7e-7a53cbf45547.jpg\">\r\n<p><strong>Key Takeaway</strong></p>\r\n<ul>\r\n<li><strong><em>Therapeutic range, </em></strong><strong>also called the '<em>therapeutic window'</em></strong> is bounded by the dose which produces <em><u>minimal therapeutic effect and the dose which produces maximal acceptable adverse effect</u></em></li>\r\n</ul>",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Competitive</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Non-competitive</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Functional</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Chemical</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 2 year old girl was brought to the emergency department by her mother after ingesting several tablets of a medication containing iron. An emergency treatment was started that included the intravenous administration of desferrioxamine. This drug is able to combine with iron in plasma to form an inactive complex and therefore to antagonize iron effects. Which of the following terms best describes this antagonism?</span></p>",
      "unique_key": "DT1292985",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292985,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><em>Chemical antagonism</em></strong> is said to occur when a <strong><em>drug combines chemically with the drug to be antagonized, making that drug pharmacologically inactive</em></strong>, as in the present example.</p>\r\n<p>A <strong><em>chemical antagonist does not act on receptors or on the pharmacokinetics of the drug to be antagonized</em></strong>.</p>\r\n<p><strong><em><u>Examples of chemical antagonism:</u></em></strong></p>\r\n<ul>\r\n<li><strong><em>KMnO4 oxidizes alkaloids-used for gastric lavage in poisoning.</em></strong></li>\r\n<li><strong><em>Tannins + alkaloids-insoluble alkaloidal tannate is formed.</em></strong></li>\r\n<li><strong><em>Chelating agents (BAL, Cal. disod. edetate) complex toxic metals (As, Pb).</em></strong></li>\r\n<li><strong><em>Nitrites form methaemoglobin which reacts with cyanide radical.</em></strong></li>\r\n</ul>\r\n<p><strong>Option A</strong>: <strong><em>Competitive antagonism</em></strong></p>\r\n<p>The antagonist is <strong><em>chemically similar to the agonist, competes with it</em></strong> and binds to the <strong>same site</strong> of the agonist molecules.</p>\r\n<p>Because the <strong><em>antagonist has affinity but no intrinsic activity</em></strong>, no response is produced and the <strong><em>log DRC of the agonist is shifted to the right</em></strong>.</p>\r\n<p><strong>Option B: <em>Noncompetitive antagonism</em></strong></p>\r\n<p>The antagonist is <strong><em>chemically unrelated to the agonist</em></strong>, binds to a <strong><em>different allosteric site altering the receptor</em></strong> in such a way that it is unable to combine with the agonist or is unable to transduce the response.</p>\r\n<p><strong><em>Increasing concentrations of the antagonist progressively flatten the agonist DRC</em></strong></p>\r\n<p><strong>Option C: <em>Physiological/functional antagonism</em></strong></p>\r\n<p>The <strong><em>two drugs act on different receptors or by different mechanisms, but have opposite overt effects on the same physiological function</em></strong>,</p>\r\n<p>i.e. have pharmacological effects in opposite direction, e.g.</p>\r\n<ul>\r\n<li><strong><em>Histamine and adrenaline on bronchial muscles and on BP.</em></strong></li>\r\n<li><strong><em> Hydrochlorothiazide and amiloride on urinary K+ excretion.</em></strong></li>\r\n<li><strong><em> Glucagon and insulin on blood sugar level.</em></strong></li>\r\n</ul>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong>Chemical antagonism</strong></li>\r\n</ul>\r\n<p><strong><em>T</em></strong><em>he two drugs react chemically and form an inactive product. </em><em>chemical antagonist does not act on receptors or on the pharmacokinetics of the drug to be antagonized</em>.</p>",
      "correct_choice_id": 154,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug A</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug B</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug C</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug D</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A pharmaceutical company develops an experimental drug which is a competitive inhibitor of the intestinal enzyme sucrase which they plan to market as therapy for diabetes. Experiments are carried out where sucrose metabolism is quantified over a range of sucrose concentrations for a system with no drug and another with the drug present. Values are determined for Vmax (g/min) and Km (mg/dL). Which of the following data sets most likely represents data from experiments with the new drug?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412219a133c4a-fdb5-47fc-a16f-e83a056bdce0.jpg\"></span></p>",
      "unique_key": "DT1292986",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292986,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><u>Competitive inhibitors</u> <strong><em>increase the Km</em></strong> of an enzyme system but do not <strong><em>change the Vmax</em></strong>.</li>\r\n<li><strong><em>Km is a representation of the binding affinity of substrate for an enzyme</em></strong>. <strong><em>Lower Km values indicate higher binding affinity</em></strong> and vice versa.</li>\r\n<li>Addition of a competitive Inhibitor lowers the binding affinity of substrate, and therefore raises the Km value for a system with both substrate and the inhibitor</li>\r\n</ul>\r\n<p><strong>Option B: </strong>In contrast, <em><u>noncompetitive inhibitors</u> <strong>lower the Vmax</strong> but <strong>do not change the Km</strong></em></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241221fbec8c46-b9d1-4593-a2c1-49dddd1fc184.jpg\">\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong><em>Competitive inhibitors increase Km value whereas non-competitive inhibitors decreases Vmax of an enzyme</em></strong></li>\r\n</ul>",
      "correct_choice_id": 163,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Phase I clinical study</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Phase II clinical study</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Phase III clinical study</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Phase IV clinical study</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An advertisement in a electronic media by a multispecialty hospital seeking to enroll 20 patients with rheumatoid arthritis in a medical study for a newly developed molecule. The study would therefore be classified under which of the following phases of clinical trials?</span></p>",
      "unique_key": "DT1292988",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292988,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em>Phase II studies are done in a small group of test subjects who have the </em><em>disease state targeted by the new drug.</em></p>\r\n<p><strong><u>Summary of Clinical trials</u></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024122160cb8292-ff6b-4285-a9f3-32702c6d9f43.jpg\">\r\n<p>Option A : Phase 1 Includes 20-100 Healthy Volunteers.</p>\r\n<p>Option C : Phase 3 Includes Upto 5000 Patients</p>\r\n<p>Option D : Phase 4 is Multicentric Includes Thousands of Patients.</p>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong><em>Phase II studies are done in a small group of test subjects who have the disease state targeted by the new drug.</em></strong></li>\r\n</ul>",
      "correct_choice_id": 172,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Fetal cardiac arrest</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Fetal hemorrhage</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Fetal malformations</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Fetal jaundice</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Regarding the drug's teratogenicity, the 4th to the 10th week of gestation is the period of time when there is the greatest concern about which sort of drug-induced fetal damage?</span></p>",
      "unique_key": "DT1292990",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292990,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><em>The 4<sup>th</sup> to 10<sup>th</sup> week of gestation is the period when <u>fetal organs</u> are&nbsp;developed.</em></strong></p>\r\n<p>Teratogenic drugs may cause fetal malformations if taken by a pregnant woman during this interval.These <strong><em>malformations include cleft palate, malformation of fingers and toes, heart defects, facial abnormalities, and skeletal deformities</em></strong>.</p>\r\n<p><strong><em>Drug-induced jaundice is primarily of concern during the last trimester of pregnancy. ( Option D )</em></strong></p>\r\n<p><strong><u>Drugs can affect the foetus at 3 stages</u></strong></p>\r\n<ul>\r\n<li><strong><em>Fertilization and implantation</em></strong> : <u>Conception to 17 days-</u>failure of pregnancy which often goes unnoticed.</li>\r\n<li><strong><em>Organogenesis</em></strong> : <u>18 to 55 days of gestation</u>, <strong><em>most vulnerable period</em></strong>, deformities are produced.</li>\r\n<li><strong><em>Growth and development</em></strong><strong> : <em>56 days onwards developmental and functional abnormalities </em></strong>can occur</li>\r\n</ul>\r\n<p><strong><u>Teratogenic Drugs</u></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024122199f80229-44ee-4bbf-8968-f401bb5d8594.jpg\">\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong>Teratogenicity</strong></li>\r\n<li><em>It refers to the <strong>capacity of a drug to cause fetal abnormalities when administered to the pregnant mother</strong>.The type of malformation depends on the drug as well as the stage at which exposure to the teratogen occurred.</em></li>\r\n</ul>",
      "correct_choice_id": 183,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">G protein</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Protein C</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Cyclic AMP</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcium</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Identify the missing substance X marked in the box in the given diagram<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241221d428eb6b-abf8-46ae-bdca-8c866b4de494.jpg\"></span></p>",
      "unique_key": "DT1292992",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292992,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><em><u>Adenylyl cyclase: cAMP</u></em></strong></p>\r\n<ul>\r\n<li><strong>Pathway Activation of Adenylyl cyclase results in intracellular accumulation of second messenger cAMP which functions mainly through cAMP-dependent protein kinase (PKA).</strong></li>\r\n<li>The <strong><em>PKA phosphorylates and alters the function of many enzymes</em></strong>, ion channels, transporters, transcription factors and structural proteins to manifest as <em>increased contractility/impulse generation (heart), relaxation </em><em>(smooth muscle), glycogenolysis, lipolysis, inhibition of secretion/mediator release, etc.</em></li>\r\n<li>In addition, <strong><em>cAMP directly opens a specific type of membrane Ca2+ channel called cyclic nucleotide gated channel (CNG) in the heart, brain and kidney.</em></strong></li>\r\n</ul>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong><em>Adenylyl cyclase</em></strong>\r\n<ul>\r\n<li><em>cAMP pathway </em>Activation of Adenylyl cyclase results in intracellular accumulation of second messenger cAMP which functions mainly through cAMP-dependent protein kinase (PKA).</li>\r\n<li>The PKA phosphorylates and alters the function of many enzymes, ion channels, transporters, transcription factors and structural proteins</li>\r\n</ul>\r\n</li>\r\n</ul>",
      "correct_choice_id": 193,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">New drug application is filled with Phase 2 clinical trials</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">Phase 0 clinical trials is for checking the pharmacokinetics of the drug</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">In Phase 3, open label studies are done</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">Phase 2 is post marketing surveillance</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements is correct about clinical trials?</span></p>",
      "unique_key": "DT1292993",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292993,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><u>Summary of Clinical trials</u></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412219ab9e458-1762-4403-837c-e92e55e4ce63.jpg\">\r\n<p><strong>Option A : </strong>New drug application is filled after Phase 3 clinical trials.</p>\r\n<p><strong>Option C : </strong>In Phase 4, open label studies are done</p>\r\n<p><strong>Option D : </strong>Phase 4 is post marketing surveillance.</p>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong>Clinical trial</strong>\r\n<ul>\r\n<li><strong><em>Clinical trial is a prospective ethically designed investigation in human subjects to objectively discover/verify/compare the results of two or more therapeutic measures (drugs)</em></strong><strong>.</strong></li>\r\n<li>Clinical trials are designed to answer one or more precisely framed questions about the value of treating equivalent groups of patients by two or more modalities (drugs, dosage regimens, other interventions). Depending on the objective of the study, clinical trials may be conducted in healthy volunteers or in volunteer patients.</li>\r\n</ul>\r\n</li>\r\n</ul>",
      "correct_choice_id": 202,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">Methyldopa</span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">Phenytoin</span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">Erythromycin</span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">Lidocaine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A newborn boy brought to paediatric department with microcephaly, a broad nasal bridge, short nose, cleft palate and hypoplasia of the distal phalanges. His mother had epilepsy during pregnancy and she had taken phenytoin for seizures, methyldopa for pregnancy-induced hypertension, and erythromycin for an upper respiratory infect ion during the first trimester. During the delivery, she had epidural anaesthesia with lidocaine. Which of the following drugs taken by the mother most likely caused the baby's presenting syndrome?</span></p>",
      "unique_key": "DT1292996",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292996,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>The <strong><em>syndrome exhibited by this newborn baby is called fetal hydantoin syndrome</em></strong> and may include nearly all possible types of malformations including microcephaly, a broad nasal bridge, short nose, cleft palate and hypoplasia of the distal phalanges.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241221cba63179-34b8-486e-a235-d4d285136f45.jpg\">\r\n<p><strong><em><u>Only category X is absolutely contraindicated in pregnancy.</u></em></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412219e40aa75-a20d-4b52-bab8-1e54c55a1348.jpg\">\r\n<p><strong>Option A</strong></p>\r\n<p><strong><em>Methyldopa is the antihypertensive of choice during pregnancy because very few adverse effects</em></strong> have been reported in neonates exposed to this drug in utero, despite its extensive use.</p>\r\n<p><strong>Option C</strong></p>\r\n<p><strong><em>Erythromycin is considered safe during pregnancy</em></strong> (FDA prenatal risk category B).</p>\r\n<p><strong>Option D</strong></p>\r\n<p>These drugs were given during the delivery, so they could not be associated with the malformations of the newborn baby.</p>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong>Teratogenicity</strong></li>\r\n<li><em>It refers to the <strong>capacity of a drug to cause foetal abnormalities when administered to the pregnant mother</strong>.The type of malformation depends on the drug as well as the stage at which exposure to the teratogen occurred.</em></li>\r\n</ul>",
      "correct_choice_id": 212,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug P</span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug Q</span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug R</span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug S</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Four new anticonvulsant drugs (P, Q, R, S) were tested in laboratory animals. It was found that all of the drugs had approximately the same lethal dose that produces death in 50% of subjects (LD50). The median effective dose of each drug is reported below: Which of the drugs most likely has the highest risk of overdose toxicity?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241221d14be9ed-f396-48de-9c46-51568cf90ec7.jpg\"></span></p>",
      "unique_key": "DT1292998",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292998,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>The risk of overdose toxicity can be estimated from the <strong><em>therapeutic index of a drug, which is the ratio between a harmful dose (LD<sub>50</sub>) and an effective dose (ED<sub>50</sub>) of that drug</em></strong></li>\r\n<li><strong><em>Therapeutic index = LD<sub>50</sub>/ED<sub>50</sub></em></strong></li>\r\n<li><strong><em>The lower the therapeutic index, the higher the risk of overdose toxicity. </em></strong>Because the lethal dose is the same for all drugs, the <strong><em>drug with the highest median effective dose will be the drug with the lowest therapeutic index</em></strong> and thus the <strong><em>highest risk of overdose </em></strong><strong><em>toxicity.</em></strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024122195b022f2-3909-4fd1-9eec-69554cde1bba.jpg\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412213854d0f9-b99c-477a-b2ef-175f6d5124ec.jpg\">\r\n<ul>\r\n<li><strong><em>Change in the table TI = LD50/ED50</em></strong></li>\r\n</ul>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong><em>The gap between the therapeutic effect DRC and the adverse effect DRC defines the safety margin or the therapeutic index of a drug. </em></strong>In experimental animals, therapeutic index is often calculated as:</li>\r\n<li><strong><em>Therapeutic index = median lethal dose/median effective dose</em></strong></li>\r\n</ul>",
      "correct_choice_id": 224,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24,
      "choices": [
        {
          "id": 231,
          "text": "<p><span style=\"font-size:12.0pt;\">Type II allergic reaction</span></p>"
        },
        {
          "id": 232,
          "text": "<p><span style=\"font-size:12.0pt;\">Delayed allergic reaction</span></p>"
        },
        {
          "id": 233,
          "text": "<p><span style=\"font-size:12.0pt;\">Idiosyncratic reaction</span></p>"
        },
        {
          "id": 234,
          "text": "<p><span style=\"font-size:12.0pt;\">Pseudoallergic reaction</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 23-year-old woman scheduled for surgical dilation and curettage was anesthetized with thiopental. Shortly after recovery from the anaesthesia, the woman had generalized seizures followed by a deep coma. On history taking, the patient's mother had suffered from acute intermittent porphyria. If the coma was caused by thiopental, which of the following drug reactions was most likely involved?</span></p>",
      "unique_key": "DT1292999",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292999,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Barbiturate-induced attacks of acute porphyria in genetically susceptible people are a well-known example of idiosyncratic drug reaction. Attacks of acute intermittent porphyria can be very serious and (rarely) fatal.</p>\r\n<p><strong><em>Idiosyncrasy refers to genetically determined abnormal reactivity to a chemical</em></strong>. As such, the type of reaction is <strong><em>restricted to individuals with a particular genotype.</em></strong></p>\r\n<p>e.g.:</p>\r\n<ul>\r\n<li><strong><em>Barbiturates cause excitement and mental confusion in some individuals.</em></strong></li>\r\n<li><strong><em> Quinine/quinidine cause cramps, diarrhoea, purpura, asthma, angioedema of face and hypotension in some patients.</em></strong></li>\r\n<li><strong><em>Chloramphenicol produces nondose-related serious aplastic anaemia in rare individuals.</em></strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024122103ba362f-3d46-43f5-a0da-ae341998f9a6.jpg\">\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><em>Idiosyncrasy refers to genetically determined abnormal reactivity to a chemical</em>. As such, the type of reaction is <em>restricted to individuals with a particular genotype.</em></li>\r\n</ul>\r\n<p><strong>ADR Types : </strong></p>\r\n<ul>\r\n<li><strong>A - Augmented</strong></li>\r\n<li><strong>B - Bizarre</strong></li>\r\n<li><strong>C - Chronic</strong></li>\r\n<li><strong>D - Delayed </strong></li>\r\n<li><strong>E - End of Rx</strong></li>\r\n<li><strong>F - Failure of Rx.</strong></li>\r\n</ul>",
      "correct_choice_id": 233,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 25,
      "choices": [
        {
          "id": 241,
          "text": "<p><span style=\"font-size:12.0pt;\">Schedule H</span></p>"
        },
        {
          "id": 242,
          "text": "<p><span style=\"font-size:12.0pt;\">Schedule G</span></p>"
        },
        {
          "id": 243,
          "text": "<p><span style=\"font-size:12.0pt;\">Schedule X</span></p>"
        },
        {
          "id": 244,
          "text": "<p><span style=\"font-size:12.0pt;\">Schedule M</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following Schedule of drug deals with 'Drugs that are given only under medical supervision'?</span></p>",
      "unique_key": "DT1293001",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293001,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong><em>Mnemonic : G For Gone If you take without medical Supervision.</em></strong></li>\r\n</ul>\r\n<p><strong><u>Schedules of Drugs</u></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241221e534fd96-17f8-4a9d-ae0b-fa489ac182bb.jpg\">\r\n<p>Option A : Schedule H Refers to Drugs that must be sold by retail <strong><em>only when a prescription by a Registered Medical Practitioner</em></strong> is produced.</p>\r\n<p>Option C : Schedule X Refers to <strong><em>Psychotropic drugs requiring special licence for manufacture and sale.</em></strong></p>\r\n<p>Option D : Schedule M Refers to <strong><em>Good manufacturing practices.</em></strong></p>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li><strong><em>Schedule G</em></strong>\r\n<ul>\r\n<li>Drugs to be labelled with the <strong><em>word 'Caution'-It is dangerous to take this preparation except under medical supervision</em></strong></li>\r\n</ul>\r\n</li>\r\n</ul>",
      "correct_choice_id": 242,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}